Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech has filed for a new Phase 1/2 pancreatic cancer cohort study, exploring the efficacy of pelareorep in combination with chemotherapy regimes, supported by a US$5M PanCAN grant. The amendment aims to investigate treatment outcomes for newly diagnosed patients with metastatic pancreatic ductal adenocarcinoma, using pelareorep with modified FOLFIRINOX and potentially atezolizumab. Positive previous study results and the potential for broad application in pancreatic cancer treatments fuel the company’s enthusiasm for this new research direction.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
